Effect of Antibiotic on Men with Raised Prostatic-Specific Antigen (4-10 ng/ml)
Background: The managing of raised Prostate-Specific Antigen (PSA) in a range of 4 to 10 ng/ml is still controversial among urologists. In addition to prostatic cancer, benign prostatic hyperplasia, and prostatitis is established to increase PSA. PSA reduction after antibiotic therapy might detect t...
        Saved in:
      
    
          | Main Authors: | Abdulsattar J. Ali, Thaker Thiab | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | University of Anbar
    
        2020-12-01 | 
| Series: | Al-Anbar Medical Journal | 
| Subjects: | |
| Online Access: | https://amj.uoanbar.edu.iq/article_170952_55ed86b3168441e84a1e5f1806a1f804.pdf | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Association between prostate-specific antigen density and prostate cancer prediction among Nigerian men        
                          
 by: Abudu EK, et al.
 Published: (2025-01-01)
- 
                
                    Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng/ml and PI-RADS ≤ 3 lesions        
                          
 by: Jia-gui Chai, et al.
 Published: (2025-01-01)
- 
                
                    Prostate Specific Antigen Level and Gleason Score in Indonesian Prostate Cancer Patients        
                          
 by: Muhammad Imam Al Kautsar Herawan, et al.
 Published: (2024-09-01)
- 
                
                    Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen        
                          
 by: Zh. R. Cherkasova, et al.
 Published: (2023-03-01)
- 
                
                    Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel        
                          
 by: Tae Hwan Kim, et al.
 Published: (2023-11-01)
 
       